Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.76 and traded as high as $1.81. Heron Therapeutics shares last traded at $1.78, with a volume of 1,155,217 shares traded.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on HRTX. StockNews.com downgraded Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, January 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 4th.
Get Our Latest Report on Heron Therapeutics
Heron Therapeutics Price Performance
The business has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $1.74. The stock has a market cap of $268.46 million, a PE ratio of -9.86 and a beta of 1.60.
Hedge Funds Weigh In On Heron Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Anfield Capital Management LLC increased its stake in shares of Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock worth $182,000 after purchasing an additional 6,264 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Heron Therapeutics by 21.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 7,927 shares in the last quarter. King Wealth Management Group increased its position in Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company's stock worth $46,000 after buying an additional 8,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Heron Therapeutics by 23.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock valued at $71,000 after buying an additional 8,684 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock worth $1,692,000 after buying an additional 9,418 shares during the last quarter. Institutional investors own 80.01% of the company's stock.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
